Admelog Purple Book BLA 209196

BLA number
209196
Proprietary names
Admelog
Proper names
insulin lispro
Applicant
Sanofi-Aventis U.S. LLC
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Admeloginsulin lispro351(a)1,000UNITS/10ML (100UNITS/ML)InjectionIntravenous, SubcutaneousMulti-Dose VialRxLicensed2017-12-11
002Admeloginsulin lispro351(a)300UNITS/3ML (100UNITS/ML)InjectionSubcutaneousAutoinjectorRxLicensed2017-12-11
003Admeloginsulin lispro351(a)300UNITS/3ML (100UNITS/ML)InjectionIntravenous, SubcutaneousMulti-Dose VialRxLicensed2018-10-19

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-05-01U001Admelog351(a)RxSanofi-Aventis U.S. LLC
2021-05-01U002Admelog351(a)RxSanofi-Aventis U.S. LLC
2021-05-01U003Admelog351(a)RxSanofi-Aventis U.S. LLC
2020-05-01R001Admelog351(a)RxSanofi-Aventis US LLC
2020-05-01R002Admelog351(a)RxSanofi-Aventis US LLC
2020-05-01R003Admelog351(a)RxSanofi-Aventis US LLC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Admelog351(a)RxLicensed2017-12-11
2020-05-01002Admelog351(a)RxLicensed2017-12-11
2020-05-01003Admelog351(a)RxLicensed2018-10-19